Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 5/20 | 0.46 |
| ▸ | FNTB | P49356 | 3/20 | 0.46 |
| ▸ | SQLE | Q14534 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487437 | 1.00 | ALOX15 (0.49) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL16221418 | 0.98 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL16221425 | 0.98 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL17554293 | 0.98 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL17554321 | 0.98 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL16221423 | 0.95 | KMT2A (0.47) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| Phosphoric Acid SCHEMBL639031 | 0.91 | FNTA (0.51) | ALOX15ALDH1A1FNTAFNTBPGGT1B | |
| SCHEMBL28220398 | 0.89 | ALOX15 (0.40) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL17554325 | 0.85 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL17554319 | 0.85 | KMT2A (0.50) | ALOX15ALDH1A1KMT2AMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20070219115-A1 | Pharmaceutical Uses of Bisphosphonates | COLEMAN ROBERT E | 2007-09-20 | — | — | US | disclosed |
| EP-1691816-A2 | PHARMACEUTICAL USES OF BISPHOSPHONATES | The University Of Sheffield (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053709-A2 | PHARMACEUTICAL USES OF BISPHOSPHONATES | UNIVERSITY OF SHEFFIELD (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219115-A1 | Pharmaceutical Uses of Bisphosphonates | BAD, TNFSF11, TNFSF10 | ALOX15 654/4885ALDH1A1 3436/4885KMT2A 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.